Both in Pharmaceuticals
Upstream Bio vs Cartesian Therapeutics
Over the past year UPB returned −86.6% and RNAC returned −22.0%; their daily moves had a correlation of 0.17.
UPB −86.6% RNAC −22.0%Growth of $1, one year, split-adjusted
| Metric | UPB | RNAC |
|---|---|---|
| Price | $3.35 | $6.34 |
| Market cap | $183.5M | $191.8M |
| Today | −1.76% | −2.31% |
| 1 month | −33.5% | −13.9% |
| 6 months | −64.0% | −8.5% |
| Year to date | −87.7% | −12.1% |
| 1 year | −87.0% | −21.8% |
| Revenue growth (YoY) | −17.5% | −100.0% |
| Gross margin | 100.0% | — |
| Net margin | −5136.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 58.1× | 129.9× |
| Net cash | $261.3M | $94.8M |
| Dividend yield | — | — |
| Volatility (60d) | 82.3% | 48.9% |
| Short % of float | 13.2% | 15.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).